AstraZeneca to list directly on NYSE while keeping U.K. listing; shares up

Published 29/09/2025, 08:42
© Reuters.

Investing.com -- AstraZeneca PLC (LON:AZN) said Monday it plans to move its U.S. trading venue to the New York Stock Exchange (NYSE), shifting from its current Nasdaq listing of American depositary receipts. The company said the change will give it access to a wider investor base.

The Anglo-Swedish drugmaker said it will remain headquartered and tax resident in the U.K., with listings in London and Stockholm intact.

Shares in AstraZeneca rose 1.5% in early London trading. 

"We set out our proposed harmonised listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York," AstraZeneca Chair Michel Demare said in a statement.

"Enabling a global listing structure will allow us to reach a broader mix of global investors."

The announcement comes after reports earlier this year suggested the company might abandon its London listing in favor of the U.S., sparking concern about the health of the U.K. market.

London has faced a steady outflow of high-profile names seeking higher valuations abroad. Recent moves include Unilever choosing Amsterdam for its ice cream spin-off, while Glencore, Petershill Partners and Ashtead have all considered or pursued alternatives to London.

AstraZeneca’s decision comes against the backdrop of intensifying political pressure on the drug industry, with U.S. President Donald Trump warning companies of heavy tariffs if they fail to expand investment and manufacturing domestically.

The company said Monday’s proposal is intended to “widen the pool of investors in AstraZeneca, especially U.S. domestic institutional and retail investors.”

The plan still requires shareholder approval, with a vote scheduled for November 3.

Earlier this month, AstraZeneca shelved plans for a £200 million ($268.8 million) expansion of its Cambridge research site, joining other pharmaceutical companies scaling back U.K. investments due to a difficult operating environment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.